AngiosarcomaSymptoms, Doctors, Treatments, Advances & More
Learn About Angiosarcoma
Condition 101 content is not available at this time, but we are continually updating the site. Please check back.
However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.
Rockefeller Outpatient Pavilion
Sandra D'angelo is an Oncologist practicing medicine in New York, New York. Dr. D'angelo is rated as an Elite provider by MediFind in the treatment of Angiosarcoma. She is also highly rated in 33 other conditions, according to our data. Her clinical expertise encompasses Synovial Sarcoma, Adult Soft Tissue Sarcoma, Liposarcoma, Merkel Cell Carcinoma, and Liver Embolization. Dr. D'angelo is currently accepting new patients.
Duke Cancer Center
Richard Riedel is an Oncologist practicing medicine in Durham, North Carolina. Dr. Riedel is rated as an Elite provider by MediFind in the treatment of Angiosarcoma. He is also highly rated in 30 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Liposarcoma, Desmoid Tumor, and Angiosarcoma. Dr. Riedel is board certified in American Board Of Internal Med, Internal Medicine and American Board Of Internal Med, Medical Oncology. Dr. Riedel is currently accepting new patients.
Rockefeller Outpatient Pavilion
William Tap is an Oncologist practicing medicine in New York, New York. Dr. Tap is rated as an Elite provider by MediFind in the treatment of Angiosarcoma. He is also highly rated in 29 other conditions, according to our data. His clinical expertise encompasses Adult Soft Tissue Sarcoma, Gastrointestinal Stromal Tumor, Angiosarcoma, Tissue Biopsy, and Liver Embolization. Dr. Tap is currently accepting new patients.
Summary: This is a multicenter, open-label study of Intratumoral Vusolimogene Oderparepvec (VO) to investigate safety and estimate when used in combination with pembrolizumab for treating participants with angiosarcoma. This is the first study evaluating this novel combination in participants with advanced angiosarcoma who have progressed after prior immunotherapy.
Summary: This is a pilot study evaluating the efficacy and safety of ivonescimab in subjects with advanced or metastatic cutaneous angiosarcoma who have previously been treated with taxane-based chemotherapy.